1
                 SECURITIES AND EXCHANGE COMMISSION
    
                      Washington, D.C.  20549
    
                           FORM 8-K
    
                         CURRENT REPORT
    
    
                 PURSUANT TO SECTION 13 OR 15(d) OF
                 THE SECURITIES EXCHANGE ACT OF 1934
    
    
    Date of Report (Date of earliest event reported) -July 12, 1996
    
               ADVANCED VIRAL RESEARCH CORP.            
       (Exact name of registrant as specified in its charter)
    
         Delaware                33-2262-A           59-2646820       
    (State or other juris-    (Commission File     (IRS Employer
    diction of incorporation)    Number)         Identification No.)
    
               1250 East Hallandale Beach Blvd.
               Suite 501,
               Hallandale, Florida                    33009   
       (Address or principal executive offices)     (Zip Code)
    
    
    Registrant's telephone number, including area code: (954)458-7636
    
    
                           None
    (Former name or former address, if changed since last report)
    2
  
    Item 1.    Changes in Control of Registrant
    
          Not Applicable
    
    Item 2.    Acquisition or Disposition of Assets
    
          Not Applicable
    
    Item 3.    Bankruptcy or Receivership
    
          Not Applicable
   
    Item 4.    Changes in Registrant's Certifying Accountant
    
          Not Applicable
    
    Item 5.    Other Events
  
          On July 11, 1996, Advanced Viral Research Corp. (the
  "Company") entered into an Addendum to Agreement (the "Addendum")
  with Avix International Pharmaceutical Corp. ("Avix") providing for
  certain amendments to the Company's distribution arrangement with
  Avix.  Among other things, the Addendum provides that Avix shall be
  the exclusive distributor of the Company's drug Reticulose in the
  territory consisting of China, Japan, Hong Kong, Taiwan and Macao
  (the "Territory"). No sales of the Company's drug Reticulose have
  been made by the Company in the Territory to date because the
  Company's drug Reticulose is not approved for sale in any of the
  countries in the Territory.  The Addendum further provides that the
  Company has granted to Avix the opportunity to retain the right to
  exclusively distribute the Company's drug Reticulose in the Territory
  (i) through June 1997 so long as Avix pays to the Company $8,000 per
  month during such twelve month period; or (ii) if the Company's drug
  Reticulose is approved for sale in any of the countries in the
  Territory.
  
    Item 6. Resignations of Registrant's Directors
    
            Not Applicable
    
    Item 7. Financial Statements and Exhibits
    
          (a)  Financial statements of business acquired
    
               None
    
          (b)  Pro forma financial information
    
               None
    
          (c)  Exhibits
    
               (1)  Addendum to Agreement dated July 11, 1996 by
  and between Advanced Viral Research Corp. and AVIX International
  Pharmaceutical Corp.
  
  
    Item 8. Change in Fiscal Year
    
            Not Applicable
    
      3
                           SIGNATURES
    
     Pursuant to the requirements of the Securities Exchange Act of
  1934, the registrant has duly caused this report to be signed on its
  behalf by the undersigned hereunto duly authorized.
    
    
                         ADVANCED VIRAL RESEARCH CORP.           
  
                         (Registrant)
    
    
    
    Dated: July 12, 1996       By:/s/William Bregman
                                     William Bregman
                                     Secretary-Treasurer
    
    
    
    
      4
                      LIST OF EXHIBITS
    
  
          (1)  Addendum to Agreement dated July 11, 1996 by and
  between Advanced Viral Research Corp. and AVIX International
  Pharmaceutical Corp.